Revenue surges 50.6% but profit stalls; margin pressure ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met qualitative 'decent summer' guidance (revenue beat 50.6%), but PAT pressure from costs/one-time items and no numeric FY27 targets to assess; Australia impairment track record clean.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Symphony delivered exceptional revenue growth (50.6% YoY, ₹378 Cr), driven by strong US/China subsidiaries and India channel normalization. However, PAT fell 4.8% YoY despite adjusted operating leverage, margins compressed by input-cost inflation (plastic, freight), and management explicitly expects near-term margin pressure amid geopolitical uncertainty (Middle East, shipping). Long-term diversification (BISP 48%) is structural, but valuation must reflect near-term headwinds.
₹378 Cr
Revenue · +50.6% YoY₹40 Cr
Reported PAT · −4.8% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenue ₹378 Cr, up 8% YoY
MISSDelivered ₹378 Cr confirmed, but YoY growth 50.6% not 8%
Domestic (India) revenue grew 15%
MISSStandalone India ₹241 Cr vs ₹229 Cr = 5.2% growth
Bonaire USA revenue grew 35%
OVERSTATED₹36 Cr vs ₹27 Cr = 33.3% growth
GSK China revenue grew 43%
OVERSTATED₹34 Cr vs ₹24 Cr = 41.7% growth
BISP now 48% of consolidated TTM revenue, ₹560 Cr
METStated on call with specifics
CTPL Australia no further capital allocation, impairment complete
METConfirmed via subsidiary performance (negative EBITDA); no growth plan
Modern trade grew over 100% due to inventory normalization
METManagement explains low base (prior year inventory overhang), explicitly cautious on sustainability
Adjusted PAT (ex one-time items) ₹43 Cr vs ₹35 Cr = +23%
METReported ₹40 Cr vs ₹42 Cr; adjusting for ₹5 Cr charge and ₹9 Cr exceptional income validates claim
Earnings quality
What changed since the last call
BISP diversification accelerated
UpgradeBISP now 48% of TTM revenue (₹560 Cr consol) vs 23% standalone; structural derisking from India-summer dependency reinforced by strong Bonaire USA (+35%) and GSK China (+43%).
Australia impairment behind; hold strategy clear
MaintainedNo further capex to Australia (CTPL negative EBITDA ₹4 Cr); strategy explicit. Balance sheet reset complete (capital employed halved FY26→FY27).
Near-term margin pressure flagged
DowngradeElevated input costs (plastic, freight, geopolitical) expected to compress margins; 7-10% price hikes taken in non-household segment insufficient to offset. Management cautious on timing of normalization.
Modern trade scaling >100%, but unsustainable
NeutralModern trade grew >100% in Q1 due to low base (prior year inventory overhang in general trade). Management explicit: 'we cannot expect this kind of growth... that's very unlikely to happen.' Temporary effect from inventory normalization.
The Q&A
Analysts pressed on sustainability (modern trade 100% growth), Australia turnaround, cost pass-through, and export headwinds. Management held measured tone, acknowledged challenges (Middle East, shipping), avoided over-assurance on margin recovery timing, and provided subsidiary granularity (revenue/EBITDA/PAT for all 4 entities). No evasion detected, but some hedging on near-term guidance ('depends on how long war lasts').
Modern trade growth drivers — Balasubramaniam
AnsweredCombination: modern trade had no channel inventory (unlike general trade with overhang). Much of the >100% is base effect from inventory normalization. Explicitly cautious: unlikely to repeat; general trade will grow once inventory clears.
Bonaire USA SKU strategy — Balasubramaniam
AnsweredRebranded India SKUs (Air Force model). Major customers Home Depot and Lowe's. Driven by right product-price-channel plus favorable Southwest US summer. Warehouse model in US vastly different from Australia installation-company model.
Cost inflation and price hikes — Haider Kachwalla
AnsweredHousehold cooler segment: no price hikes yet. Other segments: 7-10% hikes taken. Future hikes dependent on war duration and cost normalization timing. Deliberately not passing 100% to protect market share.
Australia turnaround strategy — Veenit Pasad
PartialNo new initiatives. Strategy: no additional capital deployment, maintain current operations. Management clear: whatever impairment/write-off occurred in FY26 is complete; won't happen again.
BISP product categories and scaling — Veenit Pasad
AnsweredBISP: large space ventilated coolers, tabletop fans (year-round), water heaters, exports. Already in modern retail and GT in top cities. Scaling nationwide over time. Tabletop/water heaters growing but at smaller scale; high margin.
Why coolers sell in affluent US market — Haider Kachwalla
AnsweredCoolers are not viewed as AC substitute outside India. In US, used outdoors (pool, backyard, garage), and for whole-house cooling in dry Southwest (provides humidity benefit). Portable, plug-and-play, complementary to central AC. Also sold across Europe, Middle East—premium positioning globally.
ROW business outlook next 2-3 quarters — Chat question
AnsweredMexico: two consecutive mild summers unprecedented (30-year employees never saw it). FY27 statistically almost impossible to be mild; expect robust summer and significant growth. US: if summer as good as current, sales should further increase; next year significantly better.
Export shipment recovery and geopolitical risk — Chat question
AnsweredMiddle East continues affected. Other regions: shipping costs shot up, impacting demand. Buyer sentiment cautious; landed costs up, pass-through limited. Overall: not back to normal.
Subsidiary growth trajectory next quarters — Chat question
AnsweredUS summer extends into Q2; Q3-Q4 minimal revenue (coolers seasonal). China even sales cycle (industrial coolers, exports continue). Mexico and Australia: muted. Secondary sales expected to improve only as weather normalizes.
Guidance
No explicit FY27 revenue target provided
LowManagement qualitatively guided 'decent summer' for India (delivered), expects US/China to continue if weather favorable, Mexico to rebound. No numeric FY27 target.
Q2 FY27: US summer extends, China industrial momentum continues — expect 'good' quarter
MediumUS summer extends into Sep 2026 (Q2). China has year-round industrial cycle. Both expected solid; Q3-Q4 muted (cooler seasonality).
Near-term margin pressure expected (next few quarters)
HighInput costs (plastic, freight) still elevated; geopolitical uncertainty (Middle East shipping). Management passing 7-10% price hikes in non-household segments but not all cost inflation. Normalization timing uncertain ('depends on war duration').
Long-term: margins expected to normalize once costs revert
MediumManagement expects cost normalization 'sooner or later' but won't pass 100% until certainty on duration. Implies transitory pressure.
Risks the call surfaced
Input cost inflation
MediumPlastic, freight, commodities remain elevated. Management taking 7-10% price hikes ex-household segment, but full cost recovery uncertain. Near-term margin pressure flagged explicitly.
Geopolitical uncertainty and shipping disruptions
MediumMiddle East remains affected. Shipping costs shot up globally; buyer sentiment cautious due to inability to pass cost increases. Export demand 'muted', not 'back to normal'.
Weather dependency and seasonality
HighQ1 saw patchy demand in North India due to uneven weather. US/Mexico markets summer-dependent (Q1-Q2 revenue, Q3-Q4 minimal). Mexico experienced two consecutive mild summers (unprecedented). India summer duration 4-6 weeks creates earnings lumpiness.
Australia subsidiary drag
MediumCTPL Australia revenue declining (₹27 Cr, down 13% YoY); EBITDA negative ₹4 Cr. Management strategy: no new capital, cost containment only. Impairment completed FY26, but turnaround unclear. Possible further deterioration.
Customer concentration in US market
MediumBonaire USA's growth (+35%, ₹36 Cr) driven by Home Depot and Lowe's (two largest US retailers in home-care category). Material concentration not quantified, but acknowledged as 'one major customer' (Home Depot) and 'other customer' (Lowe's). Retail consolidation or contract renegotiation could impact US growth trajectory.
Management
Score 7/10. Transparent on challenges (Australia, cost inflation, export headwinds). Candid on modern trade 100% growth being unsustainable. Specific on subsidiary numbers (revenue/EBITDA/PAT all 4 entities). Hedged on cost pass-through timing ('depends on how long war lasts'). One material discrepancy: claimed 8% revenue growth on call vs 50.6% delivered — either reporting error or significant downplay. Strong on India domestic (+15% claimed, actual 5.2% — gap unexplained). US/China subsidiaries tracking well (+35% Bonaire, +43% GSK). Australia impairment completed as promised (FY26). Inventory normalized as expected. Overall delivery mixed but credible on operational execution.
1 · Q2 FY27 (Sep 2026)
US summer extending, GSK China industrial sales continue
2 · FY27 summer (May-Jun 2027)
Mexico rebound expected (two consecutive mild summers; mean reversion)
3 · Near-term (Q2-Q4 FY27)
Commodity/input costs normalize; margin recovery dependent on war/supply normalization
Long-term diversification (BISP 48%) is structural, but valuation must reflect near-term headwinds.
Informational and educational content only. Not investment advice.